SCHEMBL799012

SCHEMBL799012

CN1CCCC(CNS(C)(=O)=O)C1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.41
PREP P48147 1/20 0.41
FAP Q12884 1/20 0.41
AURKA O14965 2/20 0.37
AURKB Q96GD4 2/20 0.37
ALDH1A1 P00352 6/20 0.37
POLB P06746 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
XPNPEP1 Q9NQW7 1/20 0.36
NSD2 O96028 1/20 0.35
PKM P14618 1/20 0.34
GAA P10253 1/20 0.34
LMNA P02545 1/20 0.34
SCN9A Q15858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17780171 0.89 NSD2 (0.42) DPP4PREPFAPAURKAAURKB
SCHEMBL14820040 0.83 KDM1A (0.38) DPP4PREPFAPNSD2
SCHEMBL799089 0.79 NSD2 (0.46) DPP4PREPFAPALDH1A1NSD2
SCHEMBL12136934 0.79 ALDH1A1 (0.46) DPP4PREPFAPALDH1A1POLB
SCHEMBL12136933 0.79 ALDH1A1 (0.46) DPP4PREPFAPALDH1A1POLB
SCHEMBL25209933 0.79 ALDH1A1 (0.46) DPP4PREPFAPALDH1A1POLB
SCHEMBL12136910 0.79 ALDH1A1 (0.46) DPP4PREPFAPALDH1A1POLB
SCHEMBL8391559 0.78 ADH1B (0.41) DPP4PREPFAPALDH1A1MEN1
SCHEMBL5783979 0.78 ADH1B (0.41) DPP4PREPFAPALDH1A1KMT2A
SCHEMBL16512312 0.77 ADH1B (0.45) DPP4PREPFAPALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11752153-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors SOUTHERN RESEARCH INSTITUTE (US) 2023-09-12 US disclosed
US-8309546-B2 Morpholinopurine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-11-13 US disclosed
US-20120071476-A1 MORPHOLINOPURINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071476-A1 MORPHOLINOPURINE DERIVATIVES MTOR, RICTOR, PIK3R1 DPP4 3216/4885PREP 3495/4885FAP 2462/4885
US-11752153-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors TXN, TXNL1, TXN2 DPP4 156/4885PREP 1014/4885FAP 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.